Japan, Jan. 28 -- BIONTECH SE,ASTELLAS PHARMA INC has got intellectual property rights for 'BISPECIFIC TRIVALENT ANTIBODIES BINDING TO CLAUDIN 6 OR CLAUDIN 18.2 AND CD3 FOR TREATMENT OF CLAUDIN-EXPRESSING CANCER DISEASES.' Other related details are as follows:

Application Number: JP,2024-017454

Category (FI): C12N5/10,C12N15/62@Z,C12N15/13,C12N15/63@Z,C07K16/46,C07K16/30,C07K16/28,C12N1/15,C12N1/19,C12N1/21,A61K39/395@C,A61K39/395@E,A61K39/395@G,A61K39/395@L,A61K39/395@T,A61K39/395@U,A61K47/46,A61K47/68,A61P35/00,A61P35/04,A61K48/00,A61K31/7088

Stage: Grant (IP right document published.)

Filing Date: Feb. 7, 2024

Publication Date: April 16, 2024

The original document can be viewed at: https://www.j-platpat.inpit.go.jp/p0100

Disclaime...